123-I ioflupane (Datscan®) presynaptic nigrostriatal imaging in patients with movement disorders
2005 ◽
Vol 48
(spe2)
◽
pp. 115-126
◽
Keyword(s):
123-I Ioflupane (Datscan®) presynaptic imaging has been shown to have a significant utility in the assessment of patients with movement disorders 123-I Ioflupane SPECT is able to distinguish between Parkinson’s disease (PD) and other forms of parkinsonism without degeneration of the nigrostriatal pathway, including a common movement disorder such as essential tremor, and to assess disease progression in PD and other neurodegenerative disorders involving the substantia nigra.
1998 ◽
Vol 89
(2)
◽
pp. 183-193
◽
2019 ◽
Vol 58
◽
pp. 3-8
◽
Keyword(s):
Keyword(s):
2015 ◽
Vol 69
(5)
◽
pp. 259-264
Keyword(s):
2017 ◽
Vol 43
◽
pp. 33-37
◽
Keyword(s):